Author(s)

Saé Muñiz-Hernández¹, Norma Hernández-Pedro¹, Omar E. Macedo-Pérez², Oscar Arrieta^1,2*

¹Experimental Oncology Laboratory, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Secretaría de Salud, Mexico City, Mexico.
²Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico.

The nuclear retinoic acid receptor may play a critical role in the process of lung carcinogenesis. Alteration or loss of nuclear retinoic acid receptors (RARs) has been associated with progression in premalignant and malignant tissues and it is associated with malignant transformation in human cells. Vitamin A derivates, such as retinoic acid, have emerged as adjuvant to therapy in several types of cancer with favorable effects. Retinoic acid regulates the expression of target genes through the binding and activation of RARs, inhibiting growth proliferation. Diverse studies have evaluated different retinoids alone or in combination with chemotherapy in lung cancer, from which results have been controversial with benefits observed only in the subpopulation with high levels of triglycerides. Additionally, several large randomized trials using retinoids to prevent tobacco-related cancer have failed; due to the latter the use of retinoids in clinical trials remains controversial. However they could reduce the risk of cancer development in non-smokers. There is evidence that retinoids have different effects on lung cancer; still the identification of biomarkers could determinate their benefits as preventive or therapy agents. This review describes the RAR alterations during the development of Non-Small Cell Lung Cancer and sets out the importance of several cancer treatments with retinoid compounds.

Cell Transformation, Neoplastic, Neoplasms, Receptors, Retinoic Acid, Biological Markers, Retinoids

Muñiz-Hernández, S. , Hernández-Pedro, N. , Macedo-Pérez, O. and Arrieta, O. (2015) Alterations in Retinoic Acid Receptors in Non-Small Cell Lung Cancer and Their Clinical Implications. Journal of Cancer Therapy, 6, 648-664. doi: 10.4236/jct.2015.68072.